Pharmacokinetics of Captopril in Healthy Subjects and in Patients with Cardiovascular Diseases

  title={Pharmacokinetics of Captopril in Healthy Subjects and in Patients with Cardiovascular Diseases},
  author={Kenneth L. Duchin and DORIS N. Mckinstry and Albert Cohen and Bruce H. Migdalof},
  journal={Clinical Pharmacokinetics},
SummaryCaptopril, the first orally active inhibitor of angiotensin-converting enzyme, is used widely in the treatment of hypertension and congestive heart failure. The pharmacokinetics of this agent have been studied extensively in healthy subjects and in patients with hypertension, congestive heart failure, and chronic renal failure. Captopril contains a sulphydryl group and binds readily to albumin and other plasma proteins. The drug also forms mixed disulphides with endogenous thiol… 

Comparative pharmacokinetics of captopril, enalapril, and quinapril.

Perindopril. A review of its pharmacokinetics and clinical pharmacology.

There is little published experience of the use of perindopril in patients with cardiac failure or other cardiac disease, but preliminary evidence would support the general value of this class of agent as adjunctive therapy.

A pharmacokinetic and pharmacodynamic evaluation of buffered sublingual captopril in patients with congestive heart failure

The data indicate that this novel administration method ofcaptopril leads to an increased rate, but an unchanged extent of captopril absorption, suggesting a modest therapeutic advantage with the use of buffered sublingual captoprill if a rapid reduction in blood pressure is required.

Antihypertensive Therapy in the Aged Patient

The dosage regimens for thiazide diuretics and amiloride must be individually titrated in the elderly patient, since the elimination of these agents decreases concurrently with decreased renal function, as indicated by compromised creatinine clearance.

Lack of Interaction Between the Peptidomimetic Substrates Captopril and Cephradine

The results of this study suggest that hPEPT1 and hPepT2 are unlikely to contribute to clinically important drug interactions in humans.

Pharmacokinetic Drug Interactions with ACE Inhibitors

SummaryAngiotensin converting enzyme (ACE) inhibitors which have active moieties excreted mainly in urine require adjustment of either the dose or the interval between doses in patients with moderate

Clinical Pharmacokinetics of Vasodilators

Understanding the mechanism of action and the pharmacokinetic properties of vasodilatory drugs facilitates optimal use in clinical practice and increases the specificity of a drug, which may result in fewer adverse effects, or more efficacy at the target site.

Effect of antihypertensive agents - captopril and nifedipine - on the functional properties of rat heart mitochondria

In vitro kinetics study revealed that antihypertensive drugs (captopril and nifedipine) directly interact with mitochondrial ATP synthase and suggested that drugs do not enter cardiomyocyte and have no direct effect on mitochondria.

The development of a stable oral solution of captopril for paediatric patients

A comprehensive study carried out in 1997 in 53 French hospitals has shown that the most frequently prescribed paediatric drugs were diphemanil, captopril, fludrocortisone, ranitidine, spironolactone and ursodeoxycholic acid.



Disposition of captopril in normal subjects

The disposition of Captopril, an angiotensin‐converting enzyme inhibitor with antihypertensive properties, was studied in 10 normal male subjects after a single 100‐mg tablet of 35S‐labeled drug.

Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients.

The lack of correlation between the relative bioavailability ofCaptopril and the induced reduction in DBP (evaluated by the corresponding AUCs) suggests that free unchanged captopril plasma monitoring is not an adequate indicator of hypertensive patients' potential responsiveness to captoprill's blood pressure lowering effects.

Influence of chronic renal failure on captopril pharmacokinetics and clinical and biological effects in hypertensive patients.

The apparent discrepancy between the lack of effects of chronic renal failure on plasma unchanged captopril bioavailability and its potentiating effects on PCEA blockade and MBP reduction may be accounted for by the renal impairment-induced accumulation ofcaptopril metabolites.

Pharmacokinetics of Captopril in Elderly Healthy Male Volunteers

Since the values for Cmax, AUC, and t1/2 were similar in the two populations, it does not appear that the pharmacokinetics of CAP are altered markedly with age alone.

Captopril kinetics in chronic congestive heart failure

Hemodynamic improvement after a single oral dose of Captopril was significant and correlated with baseline plasma renin activity (PRA), and the onset of converting‐enzyme inhibition, as determined by PRA and hemodynamic improvement correlated withCaptopril blood levels.

The influence of food intake on pharmacodynamics and plasma concentration of captopril.

There was no significant difference in blood pressure reduction whether captopril was administered in the fasting patients or together with food, indicating that the antihypertensive efficacy ofCaptopril is not markedly affected when the drug is administered with food.

Blood Concentration and Urinary Excretion of Captopril (SQ 14,225) in Patients with Chronic Renal Failure

Impairment of kidney function is suggested to be an important factor in the promotion of blood retention of captopril in patients with chronic renal failure.

Pharmacokinetics and pharmacodynamics of captopril in patients undergoing continuous ambulatory peritoneal dialysis.

The results suggest that captopril may be eliminated by CAPD, and there is a possibility that the antihypertensive effects of captoprill may be prolonged in hypertensive CAPD patients.

Pharmacokinetics of captopril and its effects on blood pressure during acute and chronic administration and in relation to food intake.

It appears that captopril can be given twice daily and together with food without loss of blood pressure control in essential hypertension.